Genexine, Inc.
Clinical-stage biotech developing long-acting therapeutics for oncology and rare diseases.
095700 | KO
Overview
Corporate Details
- ISIN(s):
- KR7095700001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙로 172 바이오이노베이션파크, 강서구
- Website:
- http://www.genexine.com/
- Sector:
- Manufacturing
Description
Genexine, Inc. is a clinical-stage biotechnology company focused on developing and commercializing immunotherapeutics and next-generation biologics. The company utilizes its proprietary hyFc® platform technology to create long-acting protein therapeutics. Its pipeline is led by GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for immuno-oncology applications. Other key assets in late-stage clinical trials include GX-E4, a long-acting treatment for anemia, and GX-H9 for growth hormone deficiency. Genexine's research and development efforts primarily target oncology and rare diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-09 00:00 |
[기재정정]사업보고서 (2022.12)
|
Korean | 721.1 KB | ||
| 2024-01-08 00:00 |
기타시장안내(연구개발 우수기업 매출액 특례적용 관련)
|
Korean | 2.7 KB | ||
| 2023-12-28 00:00 |
[기재정정]투자판단관련주요경영사항(GX-E4(지속형 빈혈 치료제)기술이전 계약체결)
|
Korean | 17.0 KB | ||
| 2023-12-22 00:00 |
투자판단관련주요경영사항(임상시험결과)(비투석 신장질환 환자의 GX-E4(빈혈치료제) 제 3상 임상시험 결과)
|
Korean | 12.7 KB | ||
| 2023-12-18 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.4 KB | ||
| 2023-12-18 00:00 |
투자판단관련주요경영사항(임상시험결과)(불응성 또는 재발성 삼중음성유방암 환자를 대상으로 pembrolizumab과 병용한 GX-I7 제1b/2…
|
Korean | 15.5 KB | ||
| 2023-12-12 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2023-11-23 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정)(GX-E4(빈혈치료제)의 국내 제 3상 임상시험계획(IND) 승인)
|
Korean | 12.2 KB | ||
| 2023-11-23 00:00 |
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정)(GX-E4(빈혈치료제)의 국내 제 3상 임상시험계획(IND) 승인)
|
Korean | 15.9 KB | ||
| 2023-11-15 00:00 |
[기재정정]분기보고서 (2023.09)
|
Korean | 1.9 MB | ||
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 1.9 MB | ||
| 2023-11-01 00:00 |
[기재정정]투자판단관련주요경영사항(GX-170의 국내1상 임상시험계획(IND) 승인)
|
Korean | 14.3 KB | ||
| 2023-10-30 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.3 KB | ||
| 2023-10-12 00:00 |
대표이사변경
|
Korean | 9.0 KB | ||
| 2023-10-12 00:00 |
주식매수선택권부여에관한신고
|
Korean | 14.0 KB |
Automate Your Workflow. Get a real-time feed of all Genexine, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Genexine, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Genexine, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
